- Home
- ROOT vs SYRE Comparison
ROOT vs SYRE Comparison
Compare ROOT & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- SYRE
- Stock Information
- Founded
- ROOT 2015
- SYRE 2013
- Country
- ROOT United States
- SYRE United States
- Employees
- ROOT N/A
- SYRE N/A
- Industry
- ROOT Property-Casualty Insurers
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- SYRE Health Care
- Exchange
- ROOT Nasdaq
- SYRE Nasdaq
- Market Cap
- ROOT 1.2B
- SYRE 1.1B
- IPO Year
- ROOT 2020
- SYRE 2016
- Fundamental
- Price
- ROOT $81.70
- SYRE $29.49
- Analyst Decision
- ROOT Buy
- SYRE Strong Buy
- Analyst Count
- ROOT 6
- SYRE 4
- Target Price
- ROOT $125.80
- SYRE $52.67
- AVG Volume (30 Days)
- ROOT 607.1K
- SYRE 621.3K
- Earning Date
- ROOT 11-05-2025
- SYRE 11-04-2025
- Dividend Yield
- ROOT N/A
- SYRE N/A
- EPS Growth
- ROOT N/A
- SYRE N/A
- EPS
- ROOT 3.34
- SYRE N/A
- Revenue
- ROOT $1,446,800,000.00
- SYRE N/A
- Revenue This Year
- ROOT $27.41
- SYRE N/A
- Revenue Next Year
- ROOT $9.74
- SYRE N/A
- P/E Ratio
- ROOT $24.38
- SYRE N/A
- Revenue Growth
- ROOT 38.50
- SYRE N/A
- 52 Week Low
- ROOT $68.08
- SYRE $10.91
- 52 Week High
- ROOT $181.14
- SYRE $29.78
- Technical
- Relative Strength Index (RSI)
- ROOT 51.80
- SYRE 76.58
- Support Level
- ROOT $68.08
- SYRE $23.01
- Resistance Level
- ROOT $91.00
- SYRE $25.42
- Average True Range (ATR)
- ROOT 6.17
- SYRE 1.73
- MACD
- ROOT 0.21
- SYRE 0.47
- Stochastic Oscillator
- ROOT 60.99
- SYRE 97.67
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.